Altamira Therapeutics Ltd. Maximum Exposure To Credit Risk
Altamira Therapeutics Ltd. (CYTOF) had Maximum Exposure To Credit Risk of $1.45 million as of 2024-12-31, per its 20-F filed 2025-04-30.
Financial Statements › Notes
ifrs-full:MaximumExposureToCreditRisk · last filed 2025-04-30
- 2023-12-31: Maximum Exposure To Credit Risk 716.32K CHF.
- 2022-12-31: Maximum Exposure To Credit Risk 216.18K CHF.
- 2021-12-31: Maximum Exposure To Credit Risk 1.46M CHF; Maximum Exposure To Credit Risk as first filed 1.26M CHF.
- 2020-12-31: Maximum Exposure To Credit Risk 11.27M CHF.
CHF
| Period end | Maximum Exposure To Credit Risk | Maximum Exposure To Credit Risk as first filed |
|---|---|---|
| 2023-12-31 | 716.32K CHF 20-F/A · filed 2024-04-22 | |
| 2022-12-31 | 216.18K CHF 20-F/A · filed 2024-04-22 | |
| 2021-12-31 | 1.46M CHF 20-F · filed 2023-05-16 | 1.26M CHF 20-F · filed 2022-04-12 |
| 2020-12-31 | 11.27M CHF 20-F · filed 2022-04-12 | |
| 2019-12-31 | 1.46M CHF 20-F · filed 2020-04-16 | |
| 2018-12-31 | 5.47M CHF 20-F · filed 2020-04-16 |
USD
| Period end | Maximum Exposure To Credit Risk |
|---|---|
| 2024-12-31 | $1.45M 20-F · filed 2025-04-30 |
| 2023-12-31 | $851.24K 20-F · filed 2025-04-30 |
| 2020-12-31 | $11.27M 20-F · filed 2021-03-31 |
| 2019-12-31 | $1.46M 20-F · filed 2021-03-31 |